期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

盐酸普拉格雷合成路线图解 被引量：8

Graphical Synthetic Routes of Prasugrel Hydrochloride
原文传递
导出
摘要 普拉格雷（prasugrel,1）,化学名为2-乙酰氧基-5-（α-环丙羰基-2-氟苄基）-4,5,6,7-四氢噻吩并[3,2-c]吡啶,是由美国礼来公司和日本第一制药三共株式会社共同研发的口服抗血小板药，临床用其盐酸盐，2009年7月经FDA批准在美国上市，商品名Efient，临床主要用于预防已接受急诊和将进行延迟经皮冠脉干预术的急性冠脉综合征患者的动脉粥样硬化性血栓形成事件。
作者 李素义 梁艳霞 陈国华
机构地区 中国药科大学药学院
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2010年第11期869-872,共4页 Chinese Journal of Pharmaceuticals
关键词 合成路线图解 盐酸盐 急性冠脉综合征 动脉粥样硬化 乙酰氧基 四氢噻吩 株式会社 血栓形成
分类号 R973.2 [医药卫生—药品]
  • 相关文献

参考文献20

  • 1Walsh S. FDA approves Effient to reduce the risk of heart attack in angioplasty patients [EB/OL]. [2009-07-10]. http:// www.fda.gov/NewsEvents/N ucm 171497.htm cements/.
  • 2马培奇.抗血小板新药普拉格雷[J].上海医药,2009,30(9):407-408. 被引量：6
  • 3孙志国,侯建,邹强,王国平,张越.普拉格雷的合成[J].中国医药工业杂志,2009,40(4):244-246. 被引量：16
  • 4Badorc A, Frehel D, Maffrand JP, et al. Derivatives of α- (2-oxo-2,4,5,6,7,7a-hexahydro thieno [3,2-c] -5-pyridyl) phenyl acetic acid, and their use as platelet and thrombotic aggregation inhibitors: US, 4740510 [P]. 1988-04-26. (CA 1986, 107: 89900).
  • 5Satyanarayana Reddy M, Eswaraiah S, Venkat Reddy G. Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts: WO, 2009066326 [P]. 2009-05-28. (CA 2009, 150: 563807).
  • 6Padi PR, Peri SRS, Ganta MR, et al. Process for the preparation of prasugrel, and its salts and polymorphs: WO, 2009062044 [P]. 2009-05-14. (CA 2009, 150: 539696).
  • 7赵志全,白文钦.氢化吡啶衍生物及其盐的制备方法:中国,101177430[P].2007-12-11.
  • 8孙志国.普拉格雷及其类似物的合成研究[C].河北科技大学硕士论文,2003.
  • 9Hana S, Josef H, Michal D, et al. A method for the manufacture of highly pure prasugrel: WO, 2010060389 [P]. 2010-06-03. (CA2010, 153: 11640).
  • 10Koike H, Asai F, Sugidachi A, et al. Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation: EP, 0542411 EP]. 1993-03-10. (CA 1994, 120: 8583).

二级参考文献10

  • 1Jakubowski JA, Winters KJ, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile [J]. Cardiovascular Drug Rev, 2007, 25 (4) : 357-374.
  • 2Alain B, Daniel F, Jean-Pierre M, et al. Derivatives of alpha- (2-oxo-2,4,5,6,7,7a-hexahydrothieno [3,2-c]-5- pyridyl)phenyl acetic acid, and their use as platelet and thrombotic aggregation inhibitiors: US, 4740510 [P]. 1988-04-26. (CA 1986, 107: 89900)
  • 3Hiroyuki K, Fumitoshi A, Atsuhiro S, et al. Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation: EP, 0542411 [P]. 1993-05-19. (CA 1993, 120: 8583)
  • 4SerebruanyVL, MideiMG, Meilman H, et al. Platelet inhibition with prasugrel (CS2747) compared with clopidogrel in patientsundergoing coronary stenting: the subset from the JUMBO study [J]. Postgrad Med J 9 2006, 82(968):404-410.
  • 5Sugidachi A, Asai F, Ogawa T, et al. The in vivo pharmacologiealprofile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties [J]. Br J Pharm acol, 2000, 129(7) : 1439-1446.
  • 6Wallentin L, Varenhorst C, James S, et al. Prasugrel achievesgreater and faster P2Y12 receptor- mediated platelet inhibition than clopidogrel due to more efficient generation of its active me2tabolite in asp irin2treated patients with coronary artery disease[J]. Eur Heart J ,2007,29(1) :21-30.
  • 7Koike H, Asai F, Sugidachi A, et al. Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their reparation and uses for inhibiting blood platelet aggregation[P]. EP0542411 ,1993-05-19.
  • 8王国平,侯建等.一种适于工业化生产的普拉格雷的制备方法[P].CN101402643.
  • 9Stepankova H,Ha. jicek J. A method of manufacturing prasugrel[P]. WO2009/006859, 2008--08--07.
  • 10陈航,闫亚非.抗血小板药物新进展[J].心血管病学进展,2009,30(1):105-109. 被引量：7

共引文献19

同被引文献43

  • 1王国平,侯建,孙志国,等.一种新型环保制备普拉格雷的方法:中国,101402642[P].2008-11-11.(CA2009,150:494842).
  • 2王国平,侯建,孙志国,等.一种适于工业生产的普拉格雷制备方法:中国,101402643[P].2008-11-11.(CA2009,150:472695).
  • 3Koike H, Asai F, Sugidachi A, et al. Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their pre- paration and uses for inhibiting blood platelet aggregation: EP, 0542411 [P]. 1993-05-19.
  • 4Ataka K, Miyata H, Kohno M, et al. 2-Silyloxy-tetra-hydroth- ienopyridine, salt thereof and process for preparing the same: US, 5874581 [P]. 1999-02-23.
  • 5Asai F, Ogawa T, Naganuma H, et al. Tetrahydrothienopyridine derivative acid addition salts:WO, 2002004461 EP]. 2002-01-17.
  • 6Asai F, Ogawa T, Naganuma H, et al. Pharmaceuticals containing salts of hydropyridine derivative: JP, 2003246735 [P]. 2003-09-02.
  • 7Brandt JT, Farid NA, Jakubowski JA, et al. 2-Acetoxy- 5- (cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetra- hydrothienoC3,2-c] pyridine pharmaceuticals for treating cardiovascular disease: WO, 2004098713 EPl. 2004-11-18.
  • 8Thijs L, Zhu J, Overeem K, et al. A process for making prasugrel: WO, 2011110219 [P]. 2011-09-15.
  • 9Spinier SA, Rees C. Review of prasugrel for the secondaryprevention of atherothrombosis [J]. J Manag Care Pharm,2009,15(5):383-395.
  • 10Jakubowski JA, Winters KJ, Naganuma H, et ah Prasugrel: a novelthienopyridine antiplatelet agent a review ofpreclinical and clinicalstudies and the mechanistic basis for its distinct antiplatelet profile[J]. Cardiovasc Drug Rev, 2007,25 ⑷:357-374.

引证文献8

二级引证文献8

中国医药工业杂志
2010年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部